Welcome to our dedicated page for Senti Biosciences news (Ticker: $SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Senti Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Senti Biosciences's position in the market.
Senti Bio reported operational updates and financial results for the first quarter of 2024, highlighting the progress in their Phase 1 clinical trial of SENTI-202 for AML and SENTI-301A for HCC in collaboration with Celest. They also presented at ASGCT 2024 Annual Meeting on platform advancements. The company reported cash and cash equivalents of $23.7 million, with R&D expenses at $8.8 million and net loss of $12.1 million for the quarter. Senti Bio plans to participate in the BIO International Convention 2024 in San Diego, CA.
Senti Bio announced the publication of preclinical data on SENTI-202, a logic-gated CAR-NK cell therapy for AML, showing improved treatment outcomes and reduced toxicity. The data supports the upcoming Phase 1 clinical trial, with patient dosing expected in Q2 2024.